v3.26.1
SHARE-BASED COMPENSATION PLAN - Phantom shares plan ("PS") and Restricted Shares (Details)
12 Months Ended
Dec. 31, 2025
BRL (R$)
shares
R$ / shares
shares
Dec. 31, 2024
BRL (R$)
shares
Dec. 31, 2023
BRL (R$)
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Non-current provisions for employee benefits | R$ R$ 332,322,000 R$ 361,974,000  
Time to calculate the average price of shares based on recent trading sessions 90 days    
PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 9,053,407 10,096,497  
Shares granted 4,012,199    
Cancelled 745,458    
Exercised (1) 4,309,831    
Available for completion 164,665    
Restricted stock, year one 2,738,509    
Restricted stock, year three 2,566,603    
Restricted stock, year four 3,583,630    
Non-current provisions for employee benefits | R$ R$ 332,322,000 R$ 361,974,000 R$ 268,489,000
Increase Provision Share Based Payment | R$ 209,842,000 196,956,000  
Decrease Provision Share Based Payment Cancelled | R$ (17,843,000) (23,470,000)  
Decrease Provision Share Based Payment | R$ R$ (221,651,000) R$ (80,001,000)  
PSO | SAR and PLUS | Top of range      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Share-based compensation arrangement by share-based payment award, award vesting period 5 years    
Phantom Share Units Psus      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Phantom Share Units Psus | R$ / shares R$ 56.57    
Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Number of other equity instruments outstanding in share-based payment arrangement 3,076,116 2,980,111  
Shares granted 563,980    
Exercised (1) 467,975    
Restricted stock, year two 504,946    
Restricted stock, year three 431,331    
Restricted stock, year four 230,773    
Non-current provisions for employee benefits | R$ R$ 80,742,000 R$ 60,226,000 26,744,000
Increase Provision Share Based Payment | R$ 45,642,000   81,276,000
Decrease Provision Share Based Payment | R$ R$ (25,126,000)   R$ (47,794,000)
Restricted share units | SAR and PLUS | Top of range      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Share-based compensation arrangement by share-based payment award, award vesting period 5 years    
Grant Year 2020 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 38.50  
Number of other equity instruments outstanding in share-based payment arrangement 33,384  
Shares granted 1,083    
Cancelled    
Exercised (1) 34,467    
Available for completion    
Restricted stock, year one    
Restricted stock, year three    
Restricted stock, year four    
Grant Year 2021 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 62.25  
Number of other equity instruments outstanding in share-based payment arrangement 7,735 874,480  
Shares granted 28,375    
Cancelled 13,046    
Exercised (1) 882,074    
Available for completion 7,735    
Restricted stock, year one    
Restricted stock, year three    
Restricted stock, year four    
Grant Year 2022 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 57.48  
Number of other equity instruments outstanding in share-based payment arrangement 480,184 3,461,437  
Shares granted 112,251    
Cancelled 109,908    
Exercised (1) 2,983,596    
Available for completion 156,930    
Restricted stock, year one 299,281    
Restricted stock, year three 23,973    
Restricted stock, year four    
Grant Year 2022 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 53.81  
Number of other equity instruments outstanding in share-based payment arrangement 115,800  
Shares granted 3,758    
Exercised (1) 119,558    
Restricted stock, year two    
Restricted stock, year three    
Grant Year 2023 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 48.84  
Number of other equity instruments outstanding in share-based payment arrangement 2,695,561 3,052,179  
Shares granted 98,965    
Cancelled 246,315    
Exercised (1) 209,268    
Available for completion    
Restricted stock, year one 2,439,228    
Restricted stock, year three 256,333    
Restricted stock, year four    
Grant Year 2023 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 51.41  
Number of other equity instruments outstanding in share-based payment arrangement 396,016 383,568  
Shares granted 12,448    
Exercised (1)    
Restricted stock, year two 277,249    
Restricted stock, year three 118,767    
Grant Year 2024 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 56.53  
Number of other equity instruments outstanding in share-based payment arrangement 2,459,390 2,675,017  
Shares granted 86,771    
Cancelled 207,385    
Exercised (1) 95,013    
Available for completion    
Restricted stock, year one    
Restricted stock, year three 2,286,297    
Restricted stock, year four 173,093    
Grant Year 2024 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 55.77  
Number of other equity instruments outstanding in share-based payment arrangement 2,212,835 2,480,743  
Shares granted 80,509    
Exercised (1) 348,417    
Restricted stock, year two 227,697    
Restricted stock, year three 312,564    
Grant Year 2025 | PSO      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 60.53  
Number of other equity instruments outstanding in share-based payment arrangement 3,410,537    
Shares granted 3,684,754    
Cancelled 168,804    
Exercised (1) 105,413    
Restricted stock, year four 3,410,537    
Grant Year 2025 | Restricted share units      
Disclosure of terms and conditions of share-based payment arrangement [line items]      
Fair value on grant date | R$   R$ 61.39  
Number of other equity instruments outstanding in share-based payment arrangement 467,265    
Shares granted 467,265    
Restricted stock, year four 230,773